Avastin

Traffic light go start restart green light

Pharma

After 3 CRLs, FDA approves Outlook's AMD drug Lytenava

The FDA has approved Outlook's Lytenava for wet age-related macular degeneration. The compound has been used off-label in the indication for two decades.

Kevin Dunleavy Jul 27, 2026 11:51am

journey path light sunshine stairs climb reach

Outlook wins FDA appeal after formal dispute proceedings

May 27, 2026 8:26am

Amneal, BioCorRx accused of ‘false and misleading’ promotions

Apr 10, 2026 8:41am

FDA endorses Merck's Keytruda for the 1st time in ovarian cancer

Feb 11, 2026 10:04am

Outlook stock plummets as FDA again snubs wet AMD drug

Aug 28, 2025 10:55am

boxing punch blow hit punching bag fight

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study

Sep 8, 2024 11:30am